#InformaticsInsider (Volume 7)

Welcome to the seventh edition of the?#InformaticsInsider!Your go-to source for all the latest developments, trends, and insights in the world of Bioinformatics and life science software.

Whether you're a Bioinformatics professional, a researcher, or just have a passion for all things biotech, Informatics Insider is here to provide you with the knowledge and expertise you need to stay ahead of the curve. In each issue, we'll bring you the latest news from the world of Bioinformatics and Life Science Software.

If you're interested in contributing to an upcoming edition or collaborating on a future project, please don't hesitate to reach out. As ever I'd love to hear from you!

Company of the week

Geneial is a biotech company that is developing a decentralized worldwide network of genomic biobanks. The company's mission is to help relieve human suffering through the acceleration of rare disease research.

The company's network of biobanks will connect researchers from all over the world to access genomic data from rare disease patients. This will allow researchers to collaborate more effectively and accelerate the development of new treatments for rare diseases.

Geneial approach is based on the principle of "genomic altruism." The company believes that everyone should have the opportunity to contribute to rare disease research, regardless of their financial or geographic circumstances.

Geneial network of biobanks is still in development, but the company has already made significant progress. The company has partnered with several leading biobanks and has received funding from the Welcome Trust and the European Commission.

On Tuesday 12 th July they announced its award of a Phase II grant from the National Institutes of Health (NIH), specifically from the National Human Genome Research Institute (NHGRI). This signifies a significant milestone in Their ongoing pursuit of advancing rare disease research and contributing to the field of genomics. Huge congratulations to Adam Hansen, PhD and the whole Geneial team on the achievement, exciting times ahead!!!!!

See link to the company website below.

https://www.geneial.com/

Collaboration of the week

TScan Therapeutics X Tempus AI

Tempus AI announced earla collaboration with TScan Therapeutics to develop a companion diagnostic test to prospectively assess human leukocyte antigen (HLA) loss in patients' tumors.?

The test would support TScan's screening protocol for its Phase I solid tumor clinical trial that is designed to enable customized mixtures of T-cell receptor engineered T-cell therapies (TCR-Ts) that are administered to patients based on tumor antigen positivity and intact HLA expression, Tempus said in a statement.

TScan Therapeutics plans to enroll patients with solid tumors including non-small cell lung cancer, melanoma, head and neck cancer, ovarian cancer, and cervical cancer. The biopharmaceutical company will use Tempus' xT assay, a 648-gene sequencing panel, to prospectively identify patients with HLA loss in the tumor to select TCR-Ts that can recognize intact HLS genes, Tempus said.

Debora Barton, MD CMO of TScan Therapeutics said in an interview "Utilizing the assay developed in collaboration with Tempus will help determine if the clinical trial participants' tumors have undergone partial HLA loss and so will enable us to choose the most appropriate TCR-Ts that are customized for the patient's tumor antigens and preserved HLA genes,"

"This CDx work is unique because we're looking for information that's not currently in the list of readouts you typically receive from next-generation sequencing of a solid tumor,"

Tempus AI Executive VP Michael Yasiejko added . "Tempus is uniquely positioned to develop a custom pipeline to extract information from standard tests that need to guide TCR-T therapy development and ultimately help identify patients that may benefit from these therapies."

Candidate of the week

Director of Commercial - 20+ years- Genomics/Life Science

• Led and managed the US field sales team, driving sales growth and exceeding targets. Hired over 65 positions and scaled team.
• Managed a?$80 million international division.
• Managed a diverse product line,?including genetic sequencers, transcriptomics tools, NGS chemistry kits, lab automation products.
• Increased sales by?$60 million in annual revenues over a 5-year period and increased overall EBIT by 12%
• Increased company’s market share from?5% and ranked 7th out of 12 competitors to 40% market share becoming the industry leader.

BS-?Microbiology/Genetics

If you have any interest in the profile above, don't hesitate to reach out, I'd be happy to make an introduction!!

Informatics news

• Illumina fined $432 Million by the European Commission for the premature acquisition of GRAIL .
• Genomenon, Inc acquires Boston Genetics
• Genomate Health seeking partners to demonstrate AI tool's precision therapy matching prowess.
• Almaden Genomics builds business operation to catch up with technology side.
• 23andMe lay off 9% of workforce to cut operating costs.
• Congenica inks Middle Eastern distribution deal with NoorDx - Diagnostics & Discovery
• Twist Bioscience inks distribution deal with MyBio Ltd .
• Geneyx Genomex Ltd. builds business on whole- genome, long- read sequencing analysis.

Do you have any thoughts, or news to share? Join the conversation on LinkedIn by following the hashtag?#InsiderInformatics.

If you're looking to add exceptional talent to your team or seeking new opportunities in the industry, please feel free to reach out to me.